Key statistics
On Friday, Vanda Pharmaceuticals Inc (VM4:STU) closed at 7.45, -1.97% below its 52-week high of 7.60, set on Jan 02, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 7.15 |
|---|---|
| High | 7.55 |
| Low | 7.00 |
| Bid | 7.50 |
| Offer | 7.55 |
| Previous close | 7.25 |
| Average volume | 2.88k |
|---|---|
| Shares outstanding | 59.11m |
| Free float | 52.40m |
| P/E (TTM) | -- |
| Market cap | 526.65m USD |
| EPS (TTM) | -3.74 USD |
Data delayed at least 15 minutes, as of Feb 27 2026.
More ▼
Press releases
- Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
- Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
- Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
- Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
- Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
- Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
- Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
- Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
- Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
- FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
More ▼
